Z Gastroenterol 2019; 57(06): 740-744
DOI: 10.1055/a-0859-7531
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Tolerability of FODMAP – reduced diet in irritable bowel syndrome – efficacy, adherence, and body weight course

Toleranz einer FODMAP – reduzierten Diät beim Reizdarmsyndrom – Effektivität, Adhärenz und Gewichtsentwicklung
Thomas Frieling
Department of Internal Medicine and Gastroenterology, Helios Klinikum Krefeld, Krefeld, Germany
,
Jürgen Heise
Department of Internal Medicine and Gastroenterology, Helios Klinikum Krefeld, Krefeld, Germany
,
Britta Krummen
Department of Internal Medicine and Gastroenterology, Helios Klinikum Krefeld, Krefeld, Germany
,
Corinna Hundorf
Department of Internal Medicine and Gastroenterology, Helios Klinikum Krefeld, Krefeld, Germany
,
Sigrid Kalde
Department of Internal Medicine and Gastroenterology, Helios Klinikum Krefeld, Krefeld, Germany
› Author Affiliations
Further Information

Publication History

28 September 2018

12 February 2019

Publication Date:
14 March 2019 (online)

Abstract

Background FODMAP reduced diet (fermentable oligo-, di-, monosaccharide, and polyols) belongs to the established therapy strategies in irritable bowel syndrome (IBS). However, disadvantages of this diet are significant and may lead to weight loss and insufficient patient adherence. Reports from Germany are not available yet.

Material and methods In a prospective study, 93 patients with IBS according to Rom III were investigated. Sixty-three patients were recruited for the study and received standardized investigation, informed consent, and structured dietary instructions about the FODMAP reduced diet. Patients complaints were documented by a validated questionnaire and a standardized Lickert scale before and 8 weeks after the start of the diet. Stool characteristics were documented by the Bristol stool form scale.

Results Patients adherence was low because 30 patients (47 %) stopped the diet. Of the remaining 33 patients, 36 % (n = 12) developed significant weight loss during the FODMAP therapy. Patients completing the study reported significant global improvement of symptoms in 79 % of cases (abdominal pain 85 %, meteorism 79 %, flatulence 69 %, borbogymi 69 %, nausea 46 %, fatigue 69 %). In addition, the severity of symptoms was significantly reduced. Fourteen patients developed changes of their stool characteristics according to the Bristol stool form scale, 11 of whom improved diarrhea and 3 improved constipation.

Conclusion FODMAP reduced diet is an efficient therapy in IBS. However, adherence of the patients is poor and the therapy bears the risk of significant weight loss.

Zusammenfassung

Hintergrund Die FODMAP-reduzierte Kost (fermentierbare Oligo-, Di-, Monosaccharide und Polyole) gehört zur etablierten Therapiestrategie beim Reizdarmsyndrom (IBS). Die Nachteile dieser Diät sind allerdings gravierend und können zum Gewichtsverlust und zur mangelnden Patientenadhärenz führen. Zahlen in Deutschland liegen allerdings hierüber nicht vor.

Patienten und Methoden In einer prospektiven Studie wurden 93 Patienten mit IBS nach Rom-III-Kriterien untersucht. 63 Patienten konnten für die Studie rekrutiert werden. Es wurde eine standardisierte Untersuchung, Aufklärung und FODMAP-Ernährungsberatung mit schriftlichem Informationsmaterial durchgeführt. Die Beschwerden wurden anhand validierter Fragebögen und einer standardisierten Lickert-Skala vor und 8 Wochen nach Beginn der Ernährungstherapie erfasst. Die Stuhleigenschaften wurden anhand der Bristol-stool-form-Skala dokumentiert.

Ergebnisse Die Patientenadhärenz war gering, da 30 Patienten (47 %) die Therapie frühzeitig beendeten. Von den 33 verbliebenen Patienten entwickelten 36 % (n = 12) einen signifikanten Gewichtsverlust unter FODMAP-Diät. Die Patienten gaben in 79 % eine signifikante globale Besserung ihrer Beschwerden (Bauchschmerzen 85 %, Blähungen 73 %, Flatulenz 69 %, Borbogymi 69 %, Übelkeit 46 %, Fatigue 69 %) an. Ebenfalls war die Schwere der Symptome signifikant reduziert. 14 Patienten entwickelten eine Veränderung ihres Stuhlverhaltens mit einer Verbesserung der durchfälligen Stühle bei 11 Patienten und der Verstopfung in 3 Fällen.

Schlussfolgerung Die FODMAP-reduzierte Kost ist eine effektive Therapie bei IBS. Allerdings ist die Patientenadhärenz gering und die Therapie kann einen signifikanten Gewichtsverlust erzeugen.

 
  • References

  • 1 Longstreth GF, Thompson WG, Chey WD. et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
  • 2 Frieling T, Fried M. Reizdarm und Reizmagen. Der Gastroenterologe 2017; 12: 106-107
  • 3 Andresen V, Frieling T. Definition des Reizdarmsyndroms. Der Gastroenterologe 2017; 12: 108-113
  • 4 Schemann M. Reizdarm und Reizmagen – Pathophysiologie und Biomarker. Der Gastroenterologe 2017; 12: 114-129
  • 5 Enck P, Frieling T, Schemann M. Irritable bowel syndrome – dissection of a disease. A 13-steps polemic. Z Gastroenterol 2017; 55: 679-684
  • 6 Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 141-162
  • 7 McKenzie YA, Alder A, Anderson W. et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012; 25: 260-274
  • 8 El-Salhy M, Ostgaard H, Gundersen D. et al. The role of diet in the pathogenesis and management of irritable bowel syndrome (review). Int J Mol Med 2012; 29: 723-773
  • 9 Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667-672
  • 10 Böhn L, Störsrud S, Liljebo T. et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 2015; 149: 1399-1407
  • 11 Shepherd SJ, Parker FC, Muir JG. et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008; 6: 765-771
  • 12 Halmos EP, Power VA, Shepherd SJ. et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75
  • 13 Biesiekierski JR, Peters SL, Newnham ED. et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328
  • 14 de Roest RH, Dobbs BR, Chapman BA. et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract 2013; 67: 895-903
  • 15 Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive review and meta-analysis. Eur J Nutr 2016; 55: 897-906
  • 16 Turco R, Salvatore S, Miele E. et al. Does a low FODMAPs diet reduce symptoms of functional abdominal pain disorders? A systematic review in adult and paediatric population, on behalf of Italian Society of Pediatrics. Ital J Pediatr 2018; 44: 53
  • 17 Cave J. Does a low FODMAP diet help IBS?. Drug Ther Bull 2015; 53: 93-96
  • 18 Pourmand H, Esmaillzadeh A. Consumption of a low fermentable oligo-, di-, mono-saccharides, and polyols diet and irritable bowel syndrome: a systematic review. Int J Prev Med 2017; 8: 104
  • 19 Dionne J, Ford AC, Yuan Y. et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Int J Prev Med 2017; 8: 104
  • 20 Altobelli E, Del Negro V, Angeletti PM. et al. Low-FODMAP Diet improves irritable bowel syndrome symptoms: a meta-analysis. Nutrients 2017; 9: E940
  • 21 Schumann D, Klose P, Lauche R. et al. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Nutrition 2018; 45: 24-31
  • 22 Whelan K, Martin LD, Staudacher HM. et al. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet 2018; 31: 239-255
  • 23 Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41: 1256-1270
  • 24 Varjú P, Farkas N, Hegyi P. et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies. PLoS One 2014; 12: e0182942
  • 25 Eswaran SL, Chey WD, Han-Markey T. et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE Guidelines in US Adults with IBSD. Am J Gastroenterol 2016; 111: 1824-1832
  • 26 Pedersen N, Andersen NN, Végh Z. et al. Ehealth: low FODMAP diet vs. Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 2014; 20: 16215-16226
  • 27 Nanayakkara WS, Skidmore PM, O’Brien L. et al. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol 2016; 9: 131-142
  • 28 Catassi TG, Lionetti E, Gatti S. et al. The Low FODMAP diet: many question marks for a catchy acronym. Nutrients 2017; 9: 292
  • 29 Marum AP, Moreira C, Tomas-Carus P. et al. A low fermentable oligo-di-mono-saccharides and polyols (FODMAP) diet is a balanced therapy for fibromyalgia with nutritional and symptomatic benefits. Nutr Hosp 2017; 34: 667-674
  • 30 Maagaard L, Ankersen DV, Végh Z. et al. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol 2016; 22: 4009-4019
  • 31 Marum AP, Moreira C, Saraiva F. et al. A low fermentable oligo-di-mono saccharides and polyols (FODMAP) diet reduced pain and improved daily life in fibromyalgia patients. Scand J Pain 2016; 13: 166-172
  • 32 Frieling T, Heise J, Krummen B. et al. FODMAP – reduzierte Diät beim Reizdarmsyndrom – Effektivität, Compliance, Gewichtsentwicklung. DGVS 2016, KV 347. Z Gastroenterol 2016; 54: 913
  • 33 Heaton KW, Thompson WG. Diagnosis. In: Heaton KW, Thompson WG. eds. Irritable Bowel Syndrome. 27. Oxford: Health Press; 1999
  • 34 Beatrice Schilling. Accessed at www.fodmap.ch
  • 35 Zuberbier T, Edenharter G, Worm M. et al. Prevalence of adverse reactions to food in Germany – a population study. Allergy 2004; 59: 338-345
  • 36 National Institute for Health and Clinical Excellence (2015). Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. Clinical Guideline 61 Update. Available at: https://www.nice.org.uk/guidance/cg61 . Accessed: December 1, 2017
  • 37 McKenzie YA, Bowyer RK, Leach H. et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016; 29: 549-575
  • 38 Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in irritable bowel syndrome. Gut 2017; 66: 1517-1527